<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602469</url>
  </required_header>
  <id_info>
    <org_study_id>R ∕18.04.172</org_study_id>
    <nct_id>NCT03602469</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesia of Magnesium Sulfate in Suprascapular Nerve Block Following Shoulder Arthroscopy</brief_title>
  <official_title>Efficacy of Magnesium Sulfate Added to Bupivacaine in Suprascapular Nerve Block on Duration of Analgesia Following Shoulder Arthroscopy: a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Arthroscopic shoulder surgeries in adults are accompanied with severe immediate
           postoperative pain reported in approximately 45% of patients. For quicker recovery and
           rehabilitation of these patients, postoperative analgesia is mandatory.

        -  Different analgesic modalities have been proposed including parenteral opioids,
           intra-articular injection of local anesthetics, interscalene brachial plexus block
           (ISB), and a suprascapular nerve block (SSNB), with varying degrees of effectiveness and
           multiple reported side effects.

        -  A recent meta-analysis demonstrates that suprascapular block results in 24-h morphine
           consumption and pain scores similar to ISB, so, it may be considered an effective and
           safe alternative for interscalene block in shoulder surgery, with less motor
           restriction, and fewer complications.

        -  Different agents are used as adjuvants to local anesthetics during peripheral nerve
           block to prolong its analgesic action including magnesium sulfate.

        -  A meta-analysis by Mengzhu et al., concluded that magnesium sulfate combined with local
           anesthetics in perineural nerve blocks provided better analgesic efficacy and may be a
           promising analgesic for perineural nerve blocks.

        -  Antinociceptive effects of magnesium are due to the regulation of calcium influx into
           the cell and a non-competitive antagonism of the NMDA receptors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the effects of magnesium sulfate as an adjuvant to
      bupivacaine in suprascapular nerve block on the duration and quality of postoperative
      analgesia following shoulder arthroscopy, postoperative pain VAS scores, intraoperative
      fentanyl requirements, sedation scores, respiratory depression, postoperative 24 hours
      cumulative morphine consumption.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of postoperative analgesia</measure>
    <time_frame>For 8 hours after suprascapular nerve block</time_frame>
    <description>time from administering the study solution in the suprascapular block till the time for the first rescue morphine request</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score at rest</measure>
    <time_frame>time 0 (after extubating) and at 30 minutes, 1 hour , 2 hours, 4hours, 6hours, 8hours,12 hours , 16hours, 20 hours and 24 hours postoperatively</time_frame>
    <description>Pain score as assessed using visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and 100 mm for worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score on shoulder abduction</measure>
    <time_frame>time 0 (after extubating) and at 30 minutes, 1 hour , 2 hours, 4hours, 6hours, 8hours,12 hours , 16hours, 20 hours and 24 hours postoperatively</time_frame>
    <description>Pain score as assessed using visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and 100 mm for worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic arterial blood pressure</measure>
    <time_frame>At baseline, immediately after induction of anaesthesia, at skin incision, every 15 minutes till the end of surgery, on arrival to PACU, then at 30, 60 minutes after surgery , every 6 hours up to 24 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic arterial blood pressure</measure>
    <time_frame>At baseline, immediately after induction of anaesthesia, at skin incision, every 15 minutes till the end of surgery, on arrival to PACU, then at 30, 60 minutes after surgery , every 6 hours up to 24 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>At baseline, immediately after induction of anaesthesia, at skin incision, every 15 minutes till the end of surgery, on arrival to PACU, then at 30, 60 minutes after surgery ,every 6 hours up to 24 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative fentanyl requirements</measure>
    <time_frame>For 5 hours after suprascapular nerve block</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation scores</measure>
    <time_frame>at 1 hour, 2 hours, and 6 hours postoperatively</time_frame>
    <description>Sedation: will be assessed using a sedation scale (awake and alert= 0; quietly awake= 1; asleep but easily roused= 2; deep asleep= 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of nausea and vomiting</measure>
    <time_frame>For 24 hours after surgery</time_frame>
    <description>Nausea will be measured using a numerical rating system (none= 0; mild= 1; moderate= 2; severe= 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vomiting episodes</measure>
    <time_frame>For 24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antiemetics received</measure>
    <time_frame>For 24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative cumulative morphine consumption</measure>
    <time_frame>For 24 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Arthroscopic Shoulder Surgery</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine-magnesium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine-magnesium</intervention_name>
    <description>Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)</description>
    <arm_group_label>Bupivacaine-magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Using propofol 1.5-2.5 mg/kg</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine-magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Ultrasound-guided suprascapular nerve block</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine-magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane 0.7-1.5 MAC in 40% oxygen</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine-magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Rocuronium 0.6 mg/kg</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine-magnesium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I-III

        Exclusion Criteria:

          -  Patient's refusal

          -  Significant cardiac diseases

          -  Significant hepatic diseases

          -  Significant renal diseases (serum creatinine ˃ 1.5 mg/dl)

          -  Cardiac conduction abnormalities

          -  Drug abuse

          -  Pregnancy

          -  Allergy to study medications

          -  Mental disease

          -  Communication barrier

          -  Coagulopathy

          -  Local skin infection

          -  Traumatic nerve injury of upper limb

          -  Patients receiving opioid analgesics

          -  Patients receiving magnesium sulfate

          -  Patients receiving beta blockers

          -  Patients receiving calcium channel blockers

          -  Previous shoulder surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanaa M Elbendary, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistant Professor, MD anesthesia Department, Faculty of Medicine, Mansoura University, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanaa M Elbendary, MD</last_name>
    <phone>00201005781768</phone>
    <email>hanaa_elbendary@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samah El Kenany, MD</last_name>
    <phone>00201002262557</phone>
    <email>sk_20022000@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mansoura University</name>
      <address>
        <city>Mansourah</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanaa M Elbendary, MD</last_name>
      <phone>00201005781768</phone>
      <email>hanaa_elbendary@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Samah El Kenany, MD</last_name>
      <phone>00201002262557</phone>
      <email>sk_20022000@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

